MOMO'S BREAKOUT BOARD

[AAAAMHIM]

VDRM .0039 THE PENNY STOCKS BEST KEPT SECRET. HOW ARE YOU IGNORING A PHARMACY STOCK WITH ONLY AN 11 MILLION FLOAT, 150 MILLION A\S....A PENDING PATENT AND MERGER??! I used to flip this from .014 to .019 just 3 months ago. It just ran from this level to 1 cent 2 weeks ago. Subs are an absolute STEAL. Someone with huge pockets is about to find this, load and sit, like I am. It's not rocket science. Unknown but not for long. THE POTENTIAL OF A BUYOUT FOR THIER DRUG IS HUGE. Converting oral medication to topical.
"has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquidtetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but has also shown to be effective in fighting methicillin-resistant Staphyloccus aureus MRSA infections." THIS IS WHY I HAVE LOADED A BOAT. I haven't been speaking about it because I have been sounding like a parrot. DID YOU SEE THAT RUN FROM .0035 TO 1 CENT LAST month on air? I was part of that. I know I know "no volume"...."don't want to get trapped"... "not liquid". BUT I ASK YOU THIS, HOW CAN YOU GET TRAPPED AT BOTTOM? LOOK at the volume (or lack of vol) the last 3 weeks...NO ONE IS SELLING DOWN HERE. I'll wait. This stock is not for the small pockets\I need to sell within a day guys. It's an INVESTMENT down here. One that, at .0039 will DOUBLE AT THE LEAST.

"ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015  

http://www.otcmarkets.com/stock/VDRM/news/ViaDerma--Inc--Announces-Plans-to-Pursue-Out-Licensing-Partnerships-in-2015?id=90438&b=y ; ;

Remember CEO has 5 STAR REVIEWS left and right  

http://m.yelp.com/biz/chris-otiko-reseda ; ;

Add in this ridiculous share structure (150 million AS! and 11 million float!) And the fact it's a PHARMACEUTICAL I think we have found a gem" t #  of 1531019 

BELOW IS JUST EXTRA STUFF...NO NEED TO READ IT.

$VDRM IS MY NEXT RXMD. Could run 500% from here. Do ur DD fellas. No kool-aid needed...REAL COMPANY EXTREMELY OVERSOLD. MOST VOLUME EVER IN ITS HISTORY last month. .02 VERY DOABLE. Multi day runner fellas. Was at 12 cents 5 months ago. PATENTS GALORE. 
ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections includingMRSA 

LOS ANGELES, Oct. 30, 2014 PRNewswire -- , a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquidtetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but has also shown to be effective in fighting methicillin-resistant Staphyloccus aureus MRSA infections. 

According to Mayo Clinic, Staph bacteria are normally found on the skin or in the nose of about one-third of the population. The bacteria are generally harmless unless they enter the body through a cut or other wound, and even then they usually cause only minor skin problems in healthy people. MRSA infection is caused by a strain of staph bacteria that's become resistant to the antibiotics commonly used to treat ordinary staphinfections. This can allow the infections to spread and sometimes become life-threatening. According to the CDC MRSA kills about 11,000 people each year in the United States. 

ViaDerma's founder and CEO Dr. Christopher Otiko comments, Initial case studies involving TetraStem have showed remarkable success. The most memorable was a woman in Florida who was on IVantibiotics for Systemic MRSA. The patient's MRSA infection was drug resistant and the usual medications were not working. However, after advising the patient to apply TetraStem directly to her neck and wrist the patient was symptom-free within two months. 

ViaDerma is currently in negotiations to test TetraStem at hospitals in Florida with plans to expand the use of the drug across America. TetraStem is currently being sold in various retail outlets. http://www.viadermalicensing.com/